Implanon Nxt (Etonogestrel)

Etonogestrel, released steadily from the implant, binds to progesterone receptors in the brain, suppressing the luteinizing hormone surge and thereby preventing ovulation. It also thickens cervical mucus and alters the uterine lining, creating multiple barriers to fertilisation and implantation.

The implant contains a fixed 68 mg dose of etonogestrel that is pre‑loaded by the manufacturer. The prescribing clinician determines whether the device is appropriate for the patient; no additional dosing adjustments are required after insertion.

Implanon Nxt is contraindicated in pregnancy; it must be removed if pregnancy occurs. For breastfeeding women, the implant is generally considered compatible, but clinicians should discuss individual risk‑benefit considerations and monitor the infant for any adverse effects.

Enquiries are submitted via the product page on gnhindia.com, where the required quantity is entered. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with daily oral contraceptives, Implanon Nxt offers continuous hormone delivery without the need for daily adherence, reducing user error. Relative to other implants, it delivers the same active ingredient (etonogestrel) and efficacy, but its single‑rod design simplifies insertion and removal.

Implanon Nxt should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain the integrity of the hormone reservoir until the time of insertion.

A trained healthcare professional inserts the 68 mg rod subdermally into the inner side of the upper arm using a sterile trocar. The procedure takes only a few minutes, after which the implant remains in place and releases etonogestrel continuously for up to three years.

Serious adverse events include deep vein thrombosis or pulmonary embolism, severe allergic reactions such as anaphylaxis, and rare cases of implant migration that may require surgical removal. Patients should seek immediate medical attention if they experience unexplained leg swelling, chest pain, severe rash, or unusual pain at the insertion site.

Women with a known hypersensitivity to etonogestrel or any component of the implant, those who are currently pregnant, have active breast cancer, or have a history of thromboembolic disorders, liver disease, or unexplained vaginal bleeding should avoid using Implanon Nxt. A thorough medical assessment is required before placement.